Trials / Recruiting
RecruitingNCT06643208
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 37 (estimated)
- Sponsor
- Fujian Provincial Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TACE-HAIC, Envafolimab and Lenvatinib | TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2027-01-01
- Completion
- 2027-03-01
- First posted
- 2024-10-16
- Last updated
- 2025-06-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06643208. Inclusion in this directory is not an endorsement.